{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:47Z","timestamp":1772165687362,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China Project","doi-asserted-by":"crossref","award":["82160348"],"award-info":[{"award-number":["82160348"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Yunnan Province Major Special Plan","award":["202302AA310018-D-8"],"award-info":[{"award-number":["202302AA310018-D-8"]}]},{"name":"Yunnan Province's Xingdian Talent Support Program Youth Talent Project","award":["XDYC-QNRC-2022-0608"],"award-info":[{"award-number":["XDYC-QNRC-2022-0608"]}]},{"name":"2024 Senior Health Technology and Medical Discipline Leader of Yunnan Provincial Health Commission","award":["D-2024056"],"award-info":[{"award-number":["D-2024056"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-025-02029-w","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:49:36Z","timestamp":1765536576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of EGFR mutation status in non-small cell lung cancer based on multiparametric MRI radiomics"],"prefix":"10.1186","volume":"25","author":[{"given":"Yubo","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiageng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxue","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bosen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"3","key":"2029_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2029_CR2","first-page":"115","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin"},{"key":"2029_CR3","doi-asserted-by":"crossref","unstructured":"Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2(1):1\u20139.","DOI":"10.1016\/j.jncc.2022.02.002"},{"issue":"1","key":"2029_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LEL Hendriks","year":"2024","unstructured":"Hendriks LEL, Remon J, Faivre-Finn C, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024;10(1):71.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2029_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2326-6066.CIR-19-0476","volume":"8","author":"M Khorrami","year":"2020","unstructured":"Khorrami M, Prasanna P, Gupta A, et al. Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in Non-Small cell lung cancer. Cancer Immunol Res. 2020;8(1):108\u201319.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2029_CR6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4143\/crt.2021.671","volume":"54","author":"YH Huang","year":"2022","unstructured":"Huang YH, Hsu KH, Chin CS, et al. The clinical outcomes of different First-Line EGFR-TKIs plus bevacizumab in advanced EGFR-Mutant lung adenocarcinoma. Cancer Res Treat. 2022;54(2):434\u201344.","journal-title":"Cancer Res Treat"},{"issue":"3 Pt 1","key":"2029_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","volume":"12","author":"GJ Riely","year":"2006","unstructured":"Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(3 Pt 1):839\u201344.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2029_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1200\/JCO.18.00131","volume":"37","author":"NA Pennell","year":"2019","unstructured":"Pennell NA, Neal JW, Chaft JE, et al. SELECT: A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor Receptor-Mutant Non-Small-Cell lung cancer. J Clin Oncol. 2019;37(2):97\u2013104.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2029_CR9","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(18)30277-7","volume":"6","author":"D Yue","year":"2018","unstructured":"Yue D, Xu S, Wang Q, et al. Erlotinib versus Vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018;6(11):863\u201373.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"2029_CR10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1200\/JCO.20.01820","volume":"39","author":"WZ Zhong","year":"2021","unstructured":"Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus Vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol. 2021;39(7):713\u201322.","journal-title":"J Clin Oncol"},{"key":"2029_CR11","doi-asserted-by":"crossref","unstructured":"Tada H, Mitsudomi T, Misumi T, et al. Randomized phase III study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage II-IIIA non-small-cell lung cancer with EGFR mutation (IMPACT). J Clin Oncol. 2022;40:231\u201341.","DOI":"10.1200\/JCO.21.01729"},{"issue":"24","key":"2029_CR12","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1158\/1078-0432.CCR-15-0354","volume":"21","author":"R Govindan","year":"2015","unstructured":"Govindan R, Mandrekar SJ, Gerber DE, et al. ALCHEMIST trials: A golden opportunity to transform outcomes in Early-Stage Non-Small cell lung cancer. Clin Cancer Res. 2015;21(24):5439\u201344.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"2029_CR13","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1158\/0008-5472.CAN-17-0122","volume":"77","author":"E Rios Velazquez","year":"2017","unstructured":"Rios Velazquez E, Parmar C, Liu Y, et al. Somatic mutations drive distinct imaging phenotypes in lung cancer. Cancer Res. 2017;77(14):3922\u201330.","journal-title":"Cancer Res"},{"issue":"1","key":"2029_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12943-019-0939-9","volume":"18","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chang L, Yang Y, et al. Intratumor heterogeneity comparison among differentsubtypes of non-small-cell lung cancer through multi-region tissue and matched Ct DNA sequencing. Mol Cancer. 2019;18(1):7.","journal-title":"Mol Cancer"},{"issue":"1","key":"2029_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-018-0772-6","volume":"17","author":"JY Hur","year":"2018","unstructured":"Hur JY, Kim HJ, Lee JS, et al. Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients. Mol Cancer. 2018;17(1):15.","journal-title":"Mol Cancer"},{"issue":"2","key":"2029_CR16","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00330-020-07141-9","volume":"31","author":"MR Chetan","year":"2021","unstructured":"Chetan MR, Gleeson FV. Radiomics in predicting treatment response in non-small-cell lung cancer: current status, challenges and future perspectives. Eur Radiol. 2021;31(2):1049\u201358.","journal-title":"Eur Radiol"},{"issue":"2","key":"2029_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41571-021-00560-7","volume":"19","author":"K Bera","year":"2022","unstructured":"Bera K, Braman N, Gupta A, et al. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat Rev Clin Oncol. 2022;19(2):132\u201346.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2029_CR18","doi-asserted-by":"publisher","first-page":"e221291","DOI":"10.1148\/radiol.221291","volume":"307","author":"Z Feng","year":"2023","unstructured":"Feng Z, Li H, Liu Q, et al. CT radiomics to predict Macrotrabecular-Massive subtype and immune status in hepatocellular carcinoma. Radiology. 2023;307(1):e221291.","journal-title":"Radiology"},{"key":"2029_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40644-023-00522-5","volume":"23","author":"CF Lu","year":"2023","unstructured":"Lu CF, Liao CY, Chao HS, et al. A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer. Cancer Imaging. 2023;23:9.","journal-title":"Cancer Imaging"},{"issue":"2","key":"2029_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00330-022-09055-0","volume":"33","author":"J Li","year":"2023","unstructured":"Li J, Qiu Z, Zhang C, et al. ITHscore: comprehensive quantification of intra-tumor heterogeneity in NSCLC by multi-scale radiomic features. Eur Radiol. 2023;33(2):893\u2013903.","journal-title":"Eur Radiol"},{"issue":"6","key":"2029_CR21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.acra.2022.06.016","volume":"30","author":"S Hou","year":"2023","unstructured":"Hou S, Fan Y, Wang X, et al. Radiomics for detection of the EGFR mutation in liver metastatic NSCLC. Acad Radiol. 2023;30(6):1039\u201346.","journal-title":"Acad Radiol"},{"key":"2029_CR22","doi-asserted-by":"publisher","first-page":"894323","DOI":"10.3389\/fonc.2022.894323","volume":"12","author":"L Yang","year":"2022","unstructured":"Yang L, Xu P, Li M, et al. PET\/CT radiomic features: A potential biomarker for EGFR mutation status and survival outcome prediction in NSCLC patients treated with TKIs. Front Oncol. 2022;12:894323.","journal-title":"Front Oncol"},{"issue":"4","key":"2029_CR23","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s00330-021-08366-y","volume":"32","author":"X Yang","year":"2022","unstructured":"Yang X, Liu M, Ren Y, et al. Using contrast-enhanced CT and non-contrast-enhanced CT to predict EGFR mutation status in NSCLC patients-a radiomics nomogram analysis. Eur Radiol. 2022;32(4):2693\u2013703.","journal-title":"Eur Radiol"},{"issue":"14","key":"2029_CR24","doi-asserted-by":"publisher","first-page":"11433","DOI":"10.3390\/ijms241411433","volume":"24","author":"M Felfli","year":"2023","unstructured":"Felfli M, Liu Y, Zerka F, et al. Systematic Review, Meta-Analysis and radiomics quality score assessment of CT radiomics-Based models predicting tumor EGFR mutation status in patients with Non-Small-Cell lung cancer. Int J Mol Sci. 2023;24(14):11433.","journal-title":"Int J Mol Sci"},{"key":"2029_CR25","doi-asserted-by":"publisher","first-page":"1281572","DOI":"10.3389\/fonc.2024.1281572","volume":"14","author":"N Ma","year":"2024","unstructured":"Ma N, Yang W, Wang Q, et al. Predictive value of 18F-FDG PET\/CT radiomics for EGFR mutation status in non-small cell lung cancer: a systematic review and meta-analysis. Front Oncol. 2024;14:1281572.","journal-title":"Front Oncol"},{"issue":"1","key":"2029_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cllc.2016.08.006","volume":"18","author":"A La Salvia","year":"2017","unstructured":"La Salvia A, Rossi A, Galetta D, et al. Intercalated chemotherapy and epidermal growth factor receptor inhibitors for patients with advanced Non-Small-cell lung cancer: A systematic review and Meta-analysis. Clin Lung Cancer. 2017;18(1):23\u201333.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"2029_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239\u201346.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2029_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40265-020-01441-6","volume":"81","author":"TS Mok","year":"2021","unstructured":"Mok TS, Cheng Y, Zhou X, et al. Updated overall survival in a randomized study comparing Dacomitinib with gefitinib as First-Line treatment in patients with advanced Non-Small-Cell lung cancer and EGFR-Activating mutations. Drugs. 2021;81(2):257\u201366.","journal-title":"Drugs"},{"key":"2029_CR29","doi-asserted-by":"publisher","first-page":"1428929","DOI":"10.3389\/fonc.2024.1428929","volume":"14","author":"Y Long","year":"2025","unstructured":"Long Y, Zhao R, Du X. Diagnostic accuracy of MRI-based radiomic features for EGFR mutation status in non-small cell lung cancer patients with brain metastases: a meta-analysis. Front Oncol. 2025;14:1428929.","journal-title":"Front Oncol"},{"issue":"9","key":"2029_CR30","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.acra.2022.12.030","volume":"30","author":"Y Li","year":"2023","unstructured":"Li Y, Lv X, Wang B, et al. Predicting EGFR T790M mutation in brain metastases using multisequence MRI-Based radiomics signature. Acad Radiol. 2023;30(9):1887\u201395.","journal-title":"Acad Radiol"},{"key":"2029_CR31","doi-asserted-by":"publisher","first-page":"111853","DOI":"10.1016\/j.ejrad.2024.111853","volume":"183","author":"Z Ouyang","year":"2025","unstructured":"Ouyang Z, Zhang G, He S, et al. CT and MRI bimodal radiomics for predicting EGFR status in NSCLC patients with brain metastases: A multicenter study. Eur J Radiol. 2025;183:111853.","journal-title":"Eur J Radiol"},{"issue":"1","key":"2029_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-024-00561-5","volume":"12","author":"X Zhang","year":"2024","unstructured":"Zhang X, Zhang G, Qiu X, et al. Exploring non-invasive precision treatment in non-small cell lung cancer patients through deep learning radiomics across imaging features and molecular phenotypes. Biomark Res. 2024;12(1):12.","journal-title":"Biomark Res"},{"issue":"6","key":"2029_CR33","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/j.acra.2023.12.024","volume":"31","author":"G Zhang","year":"2024","unstructured":"Zhang G, Man Q, Shang L, et al. Using Multi-phase CT radiomics features to predict EGFR mutation status in lung adenocarcinoma patients. Acad Radiol. 2024;31(6):2591\u2013600.","journal-title":"Acad Radiol"},{"issue":"1","key":"2029_CR34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12885-025-13823-8","volume":"25","author":"P Cao","year":"2025","unstructured":"Cao P, Jia X, Wang X, et al. Deep learning radiomics for the prediction of epidermal growth factor receptor mutation status based on MRI in brain metastasis from lung adenocarcinoma patients. BMC Cancer. 2025;25(1):443.","journal-title":"BMC Cancer"},{"issue":"10","key":"2029_CR35","doi-asserted-by":"publisher","first-page":"e2412590","DOI":"10.1002\/advs.202412590","volume":"12","author":"F Deng","year":"2025","unstructured":"Deng F, Xiao G, Tanzhu G, et al. Predicting survival rates in brain metastases patients from Non-Small cell lung cancer using radiomic signatures associated with tumor immune heterogeneity. Adv Sci (Weinh). 2025;12(10):e2412590.","journal-title":"Adv Sci (Weinh)"},{"key":"2029_CR36","doi-asserted-by":"publisher","unstructured":"Fan Y, Wang X, Dong Y, et al. Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC. Eur Radiol. 2023. https:\/\/doi.org\/10.1007\/s00330-023-09709-7.","DOI":"10.1007\/s00330-023-09709-7"},{"key":"2029_CR37","doi-asserted-by":"publisher","first-page":"1154327","DOI":"10.3389\/fonc.2023.1154327","volume":"13","author":"R Cao","year":"2023","unstructured":"Cao R, Chen H, Wang H, et al. Comprehensive analysis of prediction of the EGFR mutation and subtypes based on the spinal metastasis from primary lung adenocarcinoma. Front Oncol. 2023;13:1154327.","journal-title":"Front Oncol"},{"issue":"3","key":"2029_CR38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00234-020-02529-2","volume":"63","author":"YW Park","year":"2021","unstructured":"Park YW, An C, Lee J, et al. Diffusion tensor and Postcontrast T1-weighted imaging radiomics to differentiate the epidermal growth factor receptor mutation status of brain metastases from non-small cell lung cancer. Neuroradiology. 2021;63(3):343\u201352.","journal-title":"Neuroradiology"},{"issue":"6","key":"2029_CR39","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.21037\/jtd-20-3358","volume":"13","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wan Q, Xia X, et al. Value of radiomics model based on multi-parametric magnetic resonance imaging in predicting epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. J Thorac Dis. 2021;13(6):3497\u2013508.","journal-title":"J Thorac Dis"},{"issue":"6","key":"2029_CR40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41571-024-00891-1","volume":"21","author":"E Hoffmann","year":"2024","unstructured":"Hoffmann E, Masthoff M, Kunz WG, et al. Multiparametric MRI for characterization of the tumour microenvironment. Nat Rev Clin Oncol. 2024;21(6):428\u201348.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2029_CR41","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1007\/s00330-023-10302-1","volume":"34","author":"S Lee","year":"2024","unstructured":"Lee S, Lee CY, Kim NY, et al. Feasibility of UTE-MRI-based radiomics model for prediction of histopathologic subtype of lung adenocarcinoma: in comparison with CT-based radiomics model. Eur Radiol. 2024;34(5):3422\u201330.","journal-title":"Eur Radiol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-02029-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-025-02029-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-02029-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:49:38Z","timestamp":1765536578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12880-025-02029-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2029"],"URL":"https:\/\/doi.org\/10.1186\/s12880-025-02029-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7663043\/v1","asserted-by":"object"}]},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of the First Affiliated Hospital of Nanjing Medical University approved this retrospective study (No. 2022-NT-11) and waived the requirement of informed consent from patients. All methods were carried out in accordance with relevant guidelines and regulations. Our study adhered to the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"503"}}